Logo

Genetix Closes Acquisition of Applied Imaging

Mar 07, 2007
NEW YORK (GenomeWeb News) — Genetix last week said it has completed its acquisition of Applied Imaging.
 
Genetix plans to use the company’s protein biomarker hardware and software with its own ClonePix and CloneSelect Imager and reagents to “track the progress of drug discovery” from lab to clinic.
 
Applied Imaging’s Ariol instruments and CytoVision software are used to study tumors at the protein biomarker level to find targets, monitor responses, and predict the how a drug will work.
 
Genetix said last September it would acquire Applied Imaging for $18.3 million in cash.

Breaking News
The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.